Original Research Article

Clinical manifestations of primary pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in Japanese population

  1. Eriko Ogusa1,
  2. Naoto Tomita2,*,
  3. Yoshimi Ishii3,
  4. Hirotaka Takasaki3,
  5. Yukako Hattori4,
  6. Chihiro Matsumoto5,
  7. Yoshiaki Ishigatsubo2

Article first published online: 25 JAN 2012

DOI: 10.1002/hon.2008

Additional Information

How to Cite

Ogusa, E., Tomita, N., Ishii, Y., Takasaki, H., Hattori, Y., Matsumoto, C. and Ishigatsubo, Y. (2012), Clinical manifestations of primary pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in Japanese population. Hematol. Oncol.. doi: 10.1002/hon.2008

Author Information

  1. 1

    Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan

  2. 2

    Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

  3. 3

    Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan

  4. 4

    Department of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan

  5. 5

    Department of Hematology, Yokosuka City Hospital, Yokosuka, Japan

*Dr. Naoto Tomita, Department of Internal Medicine and Clinical Immunology,, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa, Yokohama 236-0004, Japan.
E-mail: cavalier@ch-yamate.dlenet.com

Publication History

  1. Article first published online: 25 JAN 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (105K)

Keywords:

  • MALT lymphoma;
  • lung;
  • rituximab

Abstract

We retrospectively analysed 16 cases of newly diagnosed pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma in the Japanese population. The disease was found on the basis of examination findings in 14 cases, and clinical manifestations in 2. According to the extensive staging procedure, four patients had concomitant gastric involvement. Primary treatment involved surgery alone in two patients; surgery followed by rituximab (R)-containing chemotherapy in two; R-containing chemotherapy alone in 11; and chemoradiotherapy without R in one. Over the median observation period of 28 months, disease progression was recorded in three patients, but all 16 patients were alive at the end of the observation period. One patient was treated with R alone and achieved partial remission; subsequent tentative surgery showed no evidence of residual lymphoma. It has been 72 months of progression-free survival after the diagnosis. Primary pulmonary MALT lymphoma exhibited an indolent clinical course. R has potential as a therapeutic agent in patients with pulmonary MALT lymphoma. Copyright © 2012 John Wiley & Sons, Ltd.

View Full Article (HTML) Get PDF (105K)